Evidence mapPaperPMID 42558810Full record

ReviewFrontiers in immunology2026

Integrating T cell signaling and metabolism to enhance T cell engager responses in solid tumors.

Michael Scaglione, Minal Engavale, Matthew G Chun, Deepali V Sawant, Daniel R Lu, Edward LaGory

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael ScaglioneAmgen R&D Postdoctoral Fellows Program, South San Francisco, CA, United States.
Minal EngavaleAmgen R&D Postdoctoral Fellows Program, South San Francisco, CA, United States.
Matthew G ChunAmgen R&D Postdoctoral Fellows Program, South San Francisco, CA, United States.
Deepali V SawantAmgen R&D Postdoctoral Fellows Program, South San Francisco, CA, United States.
Daniel R LuAmgen R&D Postdoctoral Fellows Program, South San Francisco, CA, United States.
Edward LaGoryAmgen R&D Postdoctoral Fellows Program, South San Francisco, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell engagers (TCEs) have delivered meaningful clinical benefit to patients, with eight molecules currently FDA-approved for hematologic malignancies and two approved for solid tumor indications. Despite their transformative potential, successful TCE development across solid tumor indications remains challenging, and additional strategies are needed to maintain T cell fitness and function within the tumor microenvironment (TME). Next-generation TCE designs aim to increase response rate and bolster durability by optimizing or delivering additional signals to T cells. In recent years, cellular metabolism has emerged as a potent regulator of T cell function and fate, shaping immunity by supporting the biochemical requirements of immunological effector functions and acting as a direct immunoregulatory signal from the TME itself. Despite this, neither cell-intrinsic nor environmental roles for metabolism in regulating TCE responses in solid tumors have been explicitly explored. We propose that metabolism is a powerful lens for understanding TCE efficacy and resistance in solid tumors, integrating signals from both surface receptors and the biochemical environment of the TME to shape T cell function and therapeutic response. In this mini-review, we highlight how three classical T cell signaling axes - 1) the T cell receptor complex, 2) costimulatory receptors, and 3) cytokine receptors - drive metabolic rewiring to license immune function and shape T cell fate. We also explore how environmental cues such as nutrients or metabolic stressors govern T cell responses, highlighting how biochemical perturbations within the TME could hamper TCE efficacy. Finally, we highlight emerging methods for dissecting metabolic contributions to TCE responses, proposing that understanding the interplay between immunological signaling, cellular metabolism, and immune programming could inform the design of next-generation TCEs for solid tumors.

Indexed as

NeoplasmsSignal TransductionT-LymphocytesAnimalsHumansLymphocyte ActivationMetabolic ReprogrammingTumor Microenvironmentimmunotherapymetabolismsignalingsolid tumorsT cell engagers (TCEs)tumor microenvironment (TME)

Identifiers

PMID42558810
PMCPMC13438312

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.